Title: "Oral contraceptive pill(OCP) treatment alters the gene expression of Intercellular
adhesion molecule-1 (ICAM-1),Tumor necrosis factor-# (TNF-#), Monocyte chemoattractant
protein-1 (MCP-1) and Plasminogen activator inhibitor-1(PAI-1) in Polycystic ovary syndrome
(PCOS) women compared to drug naive PCOS women".
Version: 1 Date: 16 Aug 2022
Reviewer's report:
Actually, the research was done and written in scientific and academic ways. It reflects huge
efforts by the researcher team and show how the they are following the ethical and legislative
issues. This research is original and can enrich the clinical sciences with very important basic
data, also, it can provide the basis for future researches in this field.
However, there are few notes need to be considered before publishing the manuscript
• The writer has a consistent tendency to write long sentences, some of them do not give the
reader a time to take a breath. So, you need to use full stop or any connecting phrases to shorten
them.
• Also, the manuscript needs proof reading, this is because the writer do not leave a space after
each full stop or comma . Please, check all the manuscript
• Introduction
1. The first reference in the introduction is old, the incidence can be changed annually. Is there
any new reference instead?
2. The second paragraph in the introduction used only one reference!!, can you add more?
• Materials and methods
2.4 Assays
You do not mention the technique by which you measured the insuline level
2.5    Calculations
1. Can you put a reference for the calculation of insuline resistance?
2. Reference 26 in which you depend to calculate the mRNA is old (2001), is there any new one?
• Results
1. Some of abbreviations need to be clarified, like FG score, SBP, DBP, etc…
2. The second paragraph in the result has long sentences and misleading. I suggest you (as shown
below) to divide it into small paragraphs to make it simple for the reader and you should put a
connector word between them like the word (and) or any other connector word
For ICAM-1 gene (CT±SD) in drug naive group (controls) was (30.59±0.72) and in post OCP
treatment  PCOS group (cases) was (29.53± 0.86) (p=<0.0001    ) and (#CT±SD) for drug
naive group (controls) was (14.12±1.08) and in post OCP treatment PCOS group (cases) was
(12.77±1.25) (p=0.0002 ). –##CT was calculated to be 1.35±0.55.
For TNF-# gene (CT±SD) in drug naive group (controls) was (25.92±0.5) and in post OCP
treatment  PCOS group (cases) was (24.88± 0.7) (p= <0.0001) and (#CT±SD) for drug
naive group (controls) was (11.05±1.08) and in post OCP treatment PCOS group (cases) was
(10.01±1.02) (p=0.001).–##CT was calculated to be 1.04±0.97.
For MCP-1 gene (CT±SD) in drug naive group (controls) was (29.81±0.73) and in post
OCP treatment PCOS group (cases) was (29.01± 0.61) (p= 0.0001) and (#CT±SD) for drug
naive group (controls) was (14.94±1.07) and in post OCP treatment PCOS group (cases) was
(14.14±1.01) (p=0.009 ). –##CT was calculated to be 0.8±0.65.
For PAI-1 gene (CT±SD) in drug naive group (controls) was (27.28±0.66) and in post OCP
treatment PCOS group (cases) was (26.96± 0.78) (p= 0.12 ) and (#CT±SD) for drug naive group
(controls) was (12.41±1.43) and in post OCP treatment PCOS group (cases) was (12.09±1.22)
(p=0.39).–##CT was calculated to be 0.32±0.87. Box and whisker plots describing the relative
expression of these genes in terms of  #Ct values  in cases verses controls are shown in figure 2.
With all the bests